First test patient gets dosed in Statera COVID drug test
FORT COLLINS — Statera Biopharma Inc. (Nasdaq: STAB), a pharmaceutical company formed this year from the merger of Cleveland BioLabs Inc. and Cytocom Inc., has provided its first test patient with a dose of its COVID-19 treatment drug candidate STAT-205.
The drug, in preclinical trials, has shown the potential to block the replication of coronaviruses in human lung cells.
Statera’s randomized, single-blind, placebo-controlled study will enroll 24 adult patients, with preliminary results expected to be reported next year.
“We look forward to working with the researchers to explore the potential of STAT-205 as an oral cost-effective therapeutic option for patients with COVID-19,” Statera CEO Michael Handley said in a prepared statement.
The company said in August that it’s evaluating or developing 21 drug candidates.
By the end of the quarter, it completed Phase 2 work on a drug for pediatric Crohn’s disease and is setting up Phase 3, to begin in early 2022.
© 2021 BizWest Media LLC
FORT COLLINS — Statera Biopharma Inc. (Nasdaq: STAB), a pharmaceutical company formed this year from the merger of Cleveland BioLabs Inc. and Cytocom Inc., has provided its first test patient with a dose of its COVID-19 treatment drug candidate STAT-205.
The drug, in preclinical trials, has shown the potential to block the replication of coronaviruses in human lung cells.
Statera’s randomized, single-blind, placebo-controlled study will enroll 24 adult patients, with preliminary results expected to be reported next year.
“We look forward to working with the researchers to explore the potential of STAT-205 as an oral cost-effective therapeutic option for patients with COVID-19,”…
Start your subscription to BizWest, The Business Journal of the Boulder Valley and Northern Colorado, TODAY!
Online access PLUS print versions of all Bizwest publications
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
- 1-year access to daily email newsletter & breaking news alerts.
Online access for one year.
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year access to daily email newsletter & breaking news alerts.
Online and print versions of all Bizwest publications PLUS premium access to BizWest Datastore for one year.
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to unlimited downloads from the BizWest Datastore!
- 1-year premium online access to the Breaking Ground website!
- 1-year access to daily email newsletter & breaking news alerts.
Premium access to the BreakingGround site plus online and print versions of all BizWest publications.
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to the Breaking Ground website!
- 1-year access to daily email newsletter & breaking news alerts.
Premium access to the BreakingGround site plus online and print versions of all BizWest publications.
One month subscription includes:
- 1-year premium online access to the Breaking Ground website!
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
- 1-year access to daily email newsletter & breaking news alerts.